304 related articles for article (PubMed ID: 18773144)
1. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Sayar H; Shen Z; Lee SJ; Royce M; Rabinowitz I; Lee F; Smith H; Eberhardt S; Maestas A; Lu H; Verschraegen C
Invest New Drugs; 2009 Apr; 27(2):153-8. PubMed ID: 18773144
[TBL] [Abstract][Full Text] [Related]
2. A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Jefford M; Michael M; Rosenthal MA; Davis ID; Green M; McClure B; Smith J; Waite B; Zalcberg J
Invest New Drugs; 2004 Apr; 22(2):185-92. PubMed ID: 14739668
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.
Goff LW; Benson AB; LoRusso PM; Tan AR; Berlin JD; Denis LJ; Benner RJ; Yin D; Rothenberg ML
Invest New Drugs; 2012 Feb; 30(1):290-8. PubMed ID: 20857171
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Mazard T; Ychou M; Thezenas S; Poujol S; Pinguet F; Thirion A; Bleuse JP; Portales F; Samalin E; Assenat E
Cancer Chemother Pharmacol; 2012 Mar; 69(3):807-14. PubMed ID: 22037922
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.
Goel S; Jhawer M; Rajdev L; Hopkins U; Fehn K; Baker C; Chun HG; Makower D; Landau L; Hoffman A; Wadler S; Mani S
Am J Clin Oncol; 2002 Oct; 25(5):528-34. PubMed ID: 12393999
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Oh SC; Sur HY; Sung HJ; Choi IK; Park SS; Seo JH; Jeen YT; Chun HJ; Shin SW; Mok YJ; Kim JS; Kim YH
Br J Cancer; 2007 May; 96(10):1514-9. PubMed ID: 17473829
[TBL] [Abstract][Full Text] [Related]
8. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
[TBL] [Abstract][Full Text] [Related]
9. A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabine.
Hirawat S; Kolitz J; Lichtman SM; Allen SL; Villani G; Gonzales A; Fricano M; Budman DR
Cancer Invest; 2007; 25(3):148-53. PubMed ID: 17530484
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Rea DW; Nortier JW; Ten Bokkel Huinink WW; Falk S; Richel DJ; Maughan T; Groenewegen G; Smit JM; Steven N; Bakker JM; Semiond D; Kerr DJ; Punt CJ
Ann Oncol; 2005 Jul; 16(7):1123-32. PubMed ID: 15939714
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; Semiond D; deJonge MJ; Eskens FA; ter Steeg J; Selleslach J; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
J Clin Oncol; 2005 Feb; 23(4):889-98. PubMed ID: 15681535
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.
Tewes M; Schleucher N; Achterrath W; Wilke HJ; Frings S; Seeber S; Harstrick A; Rustum YM; Vanhoefer U
Ann Oncol; 2003 Sep; 14(9):1442-8. PubMed ID: 12954586
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Becerra CR; Verma UN; Tran HT; Tavana D; Williams NS; Frenkel EP
Am J Clin Oncol; 2008 Jun; 31(3):219-25. PubMed ID: 18525298
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
Krishnamurthi SS; Brell JM; Hoppel CL; Egorin MJ; Weaver KC; Li X; Ingalls ST; Zuhowski EG; Schluchter MD; Dowlati A; Cooney MM; Gibbons J; Overmoyer BA; Ivy SP; Remick SC
Cancer Chemother Pharmacol; 2009 Feb; 63(3):441-50. PubMed ID: 18414865
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
19. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.
Goel S; Desai K; Karri S; Gollamudi R; Chaudhary I; Bulgaru A; Kaubisch A; Goldberg G; Einstein M; Camacho F; Baker S; Mani S
Invest New Drugs; 2007 Jun; 25(3):237-45. PubMed ID: 17195945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]